BLACKSBURG, Va., May 12, 2020 — Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Ph.D., Chairman, President and Chief Executive Officer of Landos, will present at the following upcoming investor conferences.
Event: UBS Virtual Global Healthcare Conference
Date: Tuesday, May 19, 2020
Time: 1:20 p.m. ET
Event: Jefferies Virtual Healthcare Conference
Date: Tuesday, June 2, 2020
Time: 4:00 p.m. ET
A live webcast of the UBS Virtual Global Healthcare Conference presentation will be accessible through the Company’s “Events & Presentations” page at www.landosbiopharma.com. A replay of the webcast will also be available on Landos’ website.
About Landos Biopharma
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company completed Phase 1 clinical testing in 2018 and initiated global Phase 2 clinical testing of BT-11 for ulcerative colitis (UC) in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to Phase 1 clinical testing in 2020. For more information, please visit www.landosbiopharma.com.
Chiara Russo (investors)
Rich Allan (media)